In addition, CTM can resist anoikis and immune clearance, overcome cytotoxic treatment, and maintain proliferation ability, which bestows a greater survival advantage and metastasis potential on the aggregate compared to a single tumor cell (10–13). The gene discussed is HSF4; the disease is neoplasm.